Home / Science / Heat-Proof Vaccine Trial Shows Promise
Heat-Proof Vaccine Trial Shows Promise
6 Aug
Summary
- New vaccine trial uses trehalose to stabilize vaccine components at higher temperatures.
- Early studies show equivalent immune responses to conventional vaccines, proving safe.
- Potential to reduce vaccine wastage and improve global access significantly.
Researchers are developing a novel tetanus-diphtheria vaccine that can withstand higher temperatures, a significant advancement in global health. This experimental vaccine utilizes trehalose to protect its vital components, a method explored to meet the World Health Organization's goal of a vaccine that remains viable at 30°C and 75% relative humidity.
Initial studies, directed by Prof. Saul Faust, have shown that this dried vaccine formulation provides immune responses equivalent to the conventional vaccine. It has also been deemed safe and well-tolerated in early-stage testing. The potential impact is substantial, as it could eliminate the need for strict cold chain management, thereby reducing significant wastage and improving access to vaccines worldwide.
Data from separate studies indicate that the vaccine components can survive temperature fluctuations between -20°C and +40°C. This suggests the vaccine could remain potent even after transport in cold aircraft holds and subsequent travel in hot conditions, addressing a major cause of vaccine spoilage. A larger trial involving 160 participants is slated to commence in the coming months. Given that the original vaccine is already licensed, this trial aims to validate its enhanced stability and accessibility rather than its novelty.
